ClinicalTrials.gg
RecruitingNCT07673770BWIBS-WMUpdated Jul 7, 2026

Brain Wave Informed Non-invasive Brain Stimulation: Improving Neural Networks of Working Memory in Dementia: a Proof-of-concept Study

An interventional study of EEG-triggered TMS in Dementia and Alzheimer s Disease, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Primary conditionAlzheimer DiseaseRegistry: DementiaReclassifiedWhy we changed it
Registry
Dementia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Alzheimer Disease
Why
  1. The study's listed conditions name Alzheimer Disease, a narrower term within Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by McMaster University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 321 studies in Alzheimer Disease with a site in Canada — 60 open to participants now, 81 under way, 23 of them phase 3. Alzheimer Disease · Canada.

Planned enrollment
243rd of 281
30 · median 241
Started
2026
with 14 others
No phase
68 of 321
19 open now
Primary completion
2028-04
later than 52 of 80 live
Registered
314th of 321
by date
Lead sponsor
8 of 321
McMaster University

Among the 321 studies in Alzheimer Disease with a site in Canada, this one is the 243rd largest by planned enrollment of the 281 interventional ones that give a count, is one of 15 that started in 2026, is one of 68 with no phase, reaches primary completion later than 52 of the 80 other live ones, and was the 314th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

60 of the 321 studies in Alzheimer Disease with a site in Canada are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 321 studies in Alzheimer Disease with a site in Canada, or all of them as a file.
02

Study summary

Working memory helps us hold information for a short time so one can think and make decisions. It keeps thoughts on track. As one gets older, working memory gets weaker. In people with dementia, it gets much worse, making it harder to talk with others, follow directions, or remember things like shopping lists.

This may happen because brain waves that support working memory fall out of sync. Researchers can see these brain waves using a test called EEG. In this study, the investigators will try to get these brain waves back in sync using a safe, non-invasive form of brain stimulation called transcranial magnetic stimulation (TMS), and will time it to each person's brain waves to make it more effective. The goal is to improve working memory in people with dementia. If successful, dementia patients may be able to be more independent taking pressure off their families.

Read the detailed description

Dementia is cognitive decline severe enough to interfere with daily function and is more severe than cognitive decline normally occurring as a result of aging. Two major cognitive domains which are typically impaired in dementia include executive function and learning/memory. Impairments in executive function interfere with an individual's ability to plan, organize, and switch between tasks, with impairments in this domain significantly reducing an individual's ability to perform activities of daily living (ADL). In the learning/memory domain, episodic memory and working memory are altered. Impairments in episodic memory lead to individuals being unable to recall past events or experiences, as well as being unable to learn and retain details about new experiences. Impairments in working memory lead to individuals being unable to retain information for short periods of time during the execution of a task, such as remembering what was said earlier in a conversation or remembering a set of instructions while executing them. Similar to executive function, decline in episodic and/or working memory is related to reduced ADL. Lower ADL in patients with dementia is associated with higher burden on their caregivers. Dementia caregivers in Canada provide over 580 million hours of care annually. Dementia produces a ripple effect for all Canadians through hospital stays and emergency department visits, loss of productivity from absenteeism, presenteeism, and early retirement of caregivers leading to an overall annual economic burden of over $10 billion CAD. At present, there is no gold standard treatment for reducing cognitive impairment in dementia.

While dementia is thought to be a result of a combination of structural and chemical changes in the brain, recent work has highlighted the interaction between these changes and how the brain functionally adapts to them. The 2024 Lancet Neurology Commission on dementia highlights some individuals may have the chemical and structural brain changes associated with dementia, but do not suffer cognitive decline beyond what is associated with normal aging. More specifically, a community-based autopsy study of 4,354 individuals over the age of 80 in the United Kingdom measured the number of neuropathologies including severe neuritic plaques, neurofibrillary tangles, micro \& macroinfarcts, and Lewy bodies, found that 51% of individuals with two or more significant neuropathologies did not have a clinical diagnosis of dementia. The brain's ability to withstand neuropathology without leading to cognitive decline is defined as cognitive reserve. Cognitive reserve is thought to allow recruitment of brain networks typically used for other functions or more efficient use of existing brain networks. On a neurophysiological level, it is thought that individuals with higher cognitive reserve generally have higher resting state functional connectivity between regions involved in cognition. Thus, increasing functional connectivity between brain regions involved in cognitive domains impaired in dementia may be able to improve cognitive reserve, reducing cognitive impairment in dementia.

Electroencephalography (EEG) is an effective method for measuring functional connectivity between brain regions non-invasively. EEG functional connectivity associated with proper functioning of cognitive domains impaired in dementia may provide a target biomarker to improve cognitive reserve. While EEG functional connectivity during executive function and episodic memory have been measured, there is a large degree of overlap in functional connectivity changes between executive function and working memory, likely due to both sharing some cognitive processes. Further, there are multiple studies demonstrating the causal role of EEG functional connectivity measures in working memory. Thus, EEG functional connectivity associated with working memory may provide a more promising biomarker to target for cognitive reserve.

EEG functional connectivity is a measure of the synchrony between EEG waves from two different brain regions. During successful working memory maintenance, the level of synchrony in the theta band between the frontal and temporal cortex has been shown to increase in healthy adults. Frontotemporal theta band synchrony is most commonly measured through phase-locking value (PLV). High PLV is thought to indicate stronger communication between cortices. Further, temporarily enhancing frontotemporal theta PLV using non-invasive brain stimulation known as transcranial alternating current stimulation (tACS) has been shown to restore working memory performance in older adults to the level of healthy young adults. Additionally, a metanalysis of 28 placebo-controlled studies determining the effects of different tACS protocols on working memory, found that only two forms of tACS improved working memory performance: frontotemporal theta and occipitoparietal gamma. Occipitoparietal gamma was thought to improve working memory performance as a result of many of the included studies using visual based working memory tasks. Nonetheless, these findings provide strong evidence for the role of frontotemporal theta PLV in working memory and highlight the potential for improving cognition by improving frontotemporal theta PLV long-term. At present, tACS is the only approach that can effectively improve PLV between two brain regions. However, its effects are typically temporary, lasting between 30min-70min after stimulation. Thus, enhancing PLV between two brain regions long-term may potentially produce lasting improvements in cognition in dementia.

High PLV is thought to occur due to strong synapses between two populations of neurons being recorded via EEG. If the strength of the synapses between these two populations were increased, then, theoretically their PLV would likely also increase. In the context of working memory, strengthening the synapses between neurons in the frontal and temporal cortex that generally contribute to the EEG theta band may result in a significant increase in frontotemporal theta PLV on EEG. These synapses can potentially be strengthened through a form of neuroplasticity known as long-term potentiation (LTP). LTP can potentially be induced through spike-timing dependent plasticity. Spike-timing dependent plasticity occurs through co-incident firing of the sending and receiving neurons. Considering that the frontal cortex is largely considered to be the hub for most cognitive functions, it is suggested that the frontal cortex projects onto the temporal cortex. Therefore, stimulating the frontal cortex when neurons in the temporal cortex contributing to the theta band are most likely to fire action potentials, through spike-timing dependent plasticity, may result in theta band specific LTP between the frontal and temporal cortex, in turn producing long-term enhancements in frontotemporal theta PLV.

The probability that a population of neurons will fire an action potential has previously been shown to be related to the phase of the EEG band. More specifically, non-invasive brain stimulation known as transcranial magnetic stimulation (TMS), synchronized to mu (8-13Hz) troughs results in significantly greater muscle activity than peaks or random phases. This is thought to be a result of the cortex being more excitable at troughs than any other phase. Therefore, triggering TMS over the frontal cortex at temporal cortex theta troughs, while accounting for conduction delay between the two cortices, may induce EEG theta band specific LTP between the two cortices. This approach has not been used in healthy adults or in clinical populations including Alzheimer's disease and related dementias.

The goal of this study open-label proof-of-concept study is to determine the feasibility and potential efficacy of the approach of temporal cortex theta trough triggered frontal TMS. This study will inform the design of a powered study to observe effects of EEG-TMS on working memory and will inform future work to identify and target biomarkers of other impacted cognitive domains in dementia. This study also aims to determine the potential of this technique to produce long-term improvements in working memory \& cognition in individuals suffering from dementia as well as improvements in frontotemporal theta PLV.

By improving working memory in dementia, overall cognition may be improved, dementia patients' ADL may increase, and strain on their caregivers may be reduced. This study paves the way for future work that aims to improve the cognitive domains impaired in dementia by targeting the neurophysiological biomarkers of good function in those domains. Overall, this work may provide significant benefit to individuals suffering from dementia through potentially improved cognition and independence, while also providing long-term benefits for future research aiming to improve cognition in dementia.

03

Conditions studied

  • Dementia
  • Alzheimer s Disease

Browse trials for

Keywords

  • Dementia
  • Alzheimer's Disease
  • transcranial magnetic stimulation
  • eeg
  • electroencephalography
04

In context

Alzheimer Disease Reclassified

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's planned enrollment of 30 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals must be diagnosed with Alzheimer's Disease or related dementias by a clinician.
  • Individuals must exhibit adequate oral communication skills and cognitive function sufficient to obtain a score above 10 on the
  • Instructions will be delivered in English; therefore participants must demonstrate an understanding of instruction provided in English.
  • Individuals must be at least 55 years or older

Exclusion criteria

Exclusion Criteria:

  • to TMS; presence of a pacemaker, metal/electrical/magnetic implants not including titanium, known history of untreated or uncontrolled psychological disorders, pregnancy, history of seizure or diagnoses of epilepsy, are taking any prescription medications that increase the risk of seizure.
  • Allergy to rubbing alcohol, which is needed to prepare electromyography for TMS
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Intervention: EEG-triggered TMS

    The electroencephalography (EEG) triggered transcranial magnetic stimulation (TMS) arm involves receiving TMS timed to particular phases of EEG involved in working memory. TMS involves the delivery of brief current to the part of the brain that is involved in working memory. EEG involves placing 32 electrodes on the surface of then head and reading the brain's waves in real-time. TMS will be delivered to the part of the brain involved in working memory timed to EEG recorded brain waves

    Device: EEG-triggered TMS

Interventions

  • DeviceEEG-triggered TMS

    This intervention involves delivering transcranial magnetic stimulation (TMS) to the dorsolateral prefrontal cortex (dlPFC) during working memory maintence timed to a specific electroencephalography (EEG) phase from the temporal cortex. The intervention is attempting to facilitate improved communication between the dlPFC and temporal cortex to improve working memory in people living with dementia.

07

What researchers measure

Primary outcomes

  1. Forward digit span

    A set of numbers will be presented one after another and you will be asked to recall them in the same order after a brief maintence period. Accuracy and reaction time will be measured

    Time frame: Immediately before, immediately after the 2 week intervention, 1 month and 4 months after the intervention period.

  2. Reverse digit span

    A set of digits will be presented and you must recall the digits in reverse order. Accuracy and reaction time will be measured

    Time frame: Immediately before, immediately after the 2 week intervention, 1 month and 4 months after the intervention period.

  3. Sentence span

    You will be presented with a set of sentences one after another. You are tasked with remembering the last word of each sentence. Then after a brief maintence period, you will be asked to repeat the last word of each sentence in the order the sentences were presented in. Accuracy and reaction time will be measured

    Time frame: Immediately before, immediately after the 2 week intervention, 1 month and 4 months after the intervention period.

  4. Grocery list task

    You will be presented with a set of grocery items one after another. After a brief maintence period, you will be asked to repeat the items in the same order they were presented in. Accuracy and reaction time will be measured

    Time frame: Immediately before, immediately after the 2 week intervention, 1 month and 4 months after the intervention period.

  5. Montreal Cognitive Assessment (MoCA) score

    The MOCA is a tool used to assess cognitive impairment. It assesses various aspects of cognition including executive function, memory, language, attention, and orientation. A score less than 25 out of 30 is considered significant for MCI.

    Time frame: Immediately before, immediately after the 2 week intervention, 1 month and 4 months after the intervention period.

  6. Mini-Mental State Examination (MMSE) scores

    The MMSE is a 30 point cognitive assessment that involves a variety of cognitive tasks to assess an individual's cognitive abilities. It takes 5-10 minutes to complete.

    Time frame: Immediately before, immediately after the 2 week intervention, 1 month and 4 months after the intervention period.

Secondary outcomes

  1. Frontotemporal EEG connectivity (imaginary component of coherence)

    The investigators will measure changes in the level of connectivity between the frontal and temporal cortex during working memory through electroencephalography (EEG). This metric indicates the level of communication between brain areas.

    Time frame: Recorded before, immediately after the 2 week intervention, 1 month and 4 months after the intervention period.

  2. Prefrontal theta-gamma coupling (modulation index)

    Theta-gamma coupling in the prefrontal cortex (involved in coordinating the order of items stored in working memory) during working memory will be extracted from electroencephalography (EEG) recorded during working memory maintenance.

    Time frame: Before the intervention, immediately after the 2 week intervention, 1 month and 4 months after the intervention period.

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Albert, M. S. (2011). Changes in Cognition. Neurobiology of Aging, 32(0 1), S58-S63. https://doi.org/10.1016/j.neurobiolaging.2011.09.010 Alzheimer Society of Canada. (2022, September 6). Navigating the Path Forward for Dementia in Canada: The Landmark Study Report #1. Alzheimer Society of Canada. https://alzheimer.ca/en/research/reports-dementia/navigating-path-forward-landmark-report-1 Barbey, A. K., Koenigs, M., & Grafman, J. (2013). Dorsolateral Prefrontal Contributions to Human Working Memory. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior, 49(5), 1195-1205. https://doi.org/10.1016/j.cortex.2012.05.022 Bastos, A. M., & Schoffelen, J.-M. (2016). A Tutorial Review of Functional Connectivity Analysis Methods and Their Interpretational Pitfalls. Frontiers in Systems Neuroscience, 9. https://doi.org/10.3389/fnsys.2015.00175 Casarotto, S., Fecchio, M., Rosanova, M., Varone, G., D'Ambrosio, S., Sarasso, S., Pigorini, A., Russo, S., Comanducci, A., Ilmoniemi, R. J., & Massimini, M. (2022). The rt-TEP tool: Real-time visualization of TMS-Evoked Potentials to maximize cortical activation and minimize artifacts. Journal of Neuroscience Methods, 370, 109486. https://doi.org/10.1016/j.jneumeth.2022.109486 Daume, J., Gruber, T., Engel, A. K., & Friese, U. (2017). Phase-Amplitude Coupling and Long-Range Phase Synchronization Reveal Frontotemporal Interactions during Visual Working Memory. The Journal of Neuroscience, 37(2), 313. https://doi.org/10.1523/JNEUROSCI.2130-16.2016 Eldridge, S. M., Lancaster, G. A., Campbell, M. J., Thabane, L., Hopewell, S., Coleman, C. L., & Bond, C. M. (2016). Defining Feasibility and Pilot Studies in Preparation for Randomised Controlled Trials: Development of a Conceptual Framework. PloS One, 11(3), e0150205. https://doi.org/10.1371/journal.pone.0150205 Fox, M. D., Buckner, R. L., White, M. P., Greicius, M. D., & Pascual-Leone, A. (2012). Efficacy of TMS targets for depression is related to intrinsic functional connec

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Apr 2028, 20 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 20 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Jun 29, 2026
StartEst.
Jul 7, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07673770
Responsible party
Aimee Nelson (Professor, McMaster University) — Principal investigator
First posted
Jun 29, 2026
Start date
Jul 7, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Jul 7, 2026

Study contacts

Aimee Nelson
Contact
nelsonaj@mcmaster.ca
(905) 525-9140 ext. 28053
Ameer Hamoodi
Contact
hamoodia@mcmaster.ca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion